Personalized Cancer Medicine Market to Triple by 2034, Driven by Targeted Therapies and Rising Cancer Prevalence — Zion Market Research

Event summary

The global personalized cancer medicine market was valued at USD 95.23 billion in 2024 and is projected to reach USD 279.87 billion by 2034, growing at a CAGR of 12.51%.
The personalized medicine therapeutics segment dominated the market with over 75% share in 2024, driven by demand for targeted therapies.
Hospitals accounted for around 66% of the market share in 2024, due to advanced infrastructure and high patient volume.
The Asia-Pacific region is expected to dominate the market, driven by rising cancer prevalence, infrastructure development, and regulatory support.

The big picture

The personalized cancer medicine market is experiencing significant growth due to the rising prevalence of cancer and the shift towards targeted therapies and immunotherapy. This trend is driven by the need for more effective and less invasive treatment options compared to traditional methods like chemotherapy. The market is also benefiting from increased research and development investments and the integration of advanced technologies such as AI and spatial omics. However, challenges such as high treatment costs and the lack of supportive infrastructure and skilled workforce may limit market expansion in some regions.

What we're watching

Regulatory Support: Whether regulatory frameworks will continue to support the growth of personalized cancer medicine, particularly in regions like Asia-Pacific.
Technological Advancements: The pace at which advancements in AI and Machine Learning will enhance genomic testing and precision diagnostics in the personalized cancer medicine market.
Cost Barriers: How the high cost of personalized therapies will impact market adoption trends, especially in economically uncertain regions.